{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:02:10Z","timestamp":1790431330910,"version":"4.1.0"},"reference-count":90,"publisher":"American Society for Microbiology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Traditionally, the design of new vaccines directed against<jats:named-content content-type=\"genus-species\">Mycobacterium tuberculosis<\/jats:named-content>, the most successful bacterial pathogen on the planet, has focused on prophylactic candidates that would be given to individuals while they are still young. It is becoming more apparent, however, that there are several types of vaccine candidates now under development that could be used under various conditions. Thus, in addition to prophylactic vaccines, such as recombinant<jats:named-content content-type=\"genus-species\">Mycobacterium bovis<\/jats:named-content>BCG or BCG-boosting vaccines, other applications include vaccines that could prevent infection, vaccines that could be given in emergency situations as postexposure vaccines, vaccines that could be used to facilitate chemotherapy, and vaccines that could be used to reduce or prevent relapse and reactivation disease. These approaches are discussed here, including the type of immunity we are trying to specifically target, as well as the limitations of these approaches.<\/jats:p>","DOI":"10.1128\/cvi.00718-14","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T05:58:17Z","timestamp":1419487097000},"page":"249-257","source":"Crossref","is-referenced-by-count":40,"title":["Tuberculosis Vaccine Types and Timings"],"prefix":"10.1128","volume":"22","author":[{"given":"Ian M.","family":"Orme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2014,12,24]]},"reference":[{"key":"key20180919073757_B1","volume-title":"Global tuberculosis report 2013","author":"World Health Organization","year":"2013"},{"key":"key20180919073757_B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1586\/17476348.3.1.67","article-title":"Mathematical models of the epidemiology and control of drug-resistant TB","volume":"3","year":"2009","journal-title":"Expert Rev Respir Med"},{"key":"key20180919073757_B3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrmicro2048","article-title":"Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis","volume":"7","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"key20180919073757_B4","first-page":"789","article-title":"The BCG vaccine","volume-title":"Vaccines","year":"2012","edition":"6th ed."},{"key":"key20180919073757_B5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(14)70033-5","article-title":"Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review","volume":"2","year":"2014","journal-title":"Lancet Respir Med"},{"key":"key20180919073757_B6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-3519(99)80013-5","article-title":"Vaccination against tuberculosis: recent progress","volume":"41","year":"1999","journal-title":"Adv Vet Med"},{"key":"key20180919073757_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.70.1.1","article-title":"The search for new vaccines against tuberculosis","volume":"70","year":"2001","journal-title":"J Leukoc Biol"},{"key":"key20180919073757_B8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40265-013-0081-8","article-title":"Vaccine development for tuberculosis: current progress","volume":"73","year":"2013","journal-title":"Drugs"},{"key":"key20180919073757_B9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Team MATS","year":"2013","journal-title":"Lancet"},{"key":"key20180919073757_B10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.tube.2013.11.003","article-title":"A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data","volume":"94","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2014.10.008","article-title":"Vaccines to prevent tuberculosis infection rather than disease: physiological and immunological aspects","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2567.2004.01809.x","article-title":"Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs","volume":"111","year":"2004","journal-title":"Immunology"},{"key":"key20180919073757_B13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/intimm\/dxg091","article-title":"Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis","volume":"15","year":"2003","journal-title":"Int Immunol"},{"key":"key20180919073757_B14","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Gu\u00e9rin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073757_B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tube.2013.07.004","article-title":"A new unifying theory of the pathogenesis of tuberculosis","volume":"94","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri3259","article-title":"The immunological life cycle of tuberculosis","volume":"12","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"key20180919073757_B17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.tube.2005.11.003","article-title":"Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis","volume":"86","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/emmm.201000125","article-title":"Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis","volume":"3","year":"2011","journal-title":"EMBO Mol Med"},{"key":"key20180919073757_B19","first-page":"65","article-title":"Granuloma formation in mouse and guinea pig models of experimental tuberculosis","volume-title":"Granulomatous infections and inflammation: cellular and molecular mechanisms","year":"2003"},{"key":"key20180919073757_B20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1128\/IAI.71.2.864-871.2003","article-title":"Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis","volume":"71","year":"2003","journal-title":"Infect Immun"},{"key":"key20180919073757_B21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/fmb.10.168","article-title":"Development of new vaccines and drugs for TB: limitations and potential strategic errors","volume":"6","year":"2011","journal-title":"Future Microbiol"},{"key":"key20180919073757_B22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/infdis\/167.6.1481","article-title":"T cell response to Mycobacterium tuberculosis","volume":"167","year":"1993","journal-title":"J Infect Dis"},{"key":"key20180919073757_B23","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1073\/pnas.250480397","article-title":"Recombinant bacillus Calmette-Gu\u00e9rin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model","volume":"97","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073757_B24","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e9rin mutants that secrete listeriolysin","volume":"115","year":"2005","journal-title":"J Clin Invest"},{"key":"key20180919073757_B25","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nm906","article-title":"Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis","volume":"9","year":"2003","journal-title":"Nat Med"},{"key":"key20180919073757_B26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1089\/jir.2005.25.694","article-title":"Hypervirulent M. tuberculosis W\/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway","volume":"25","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"key20180919073757_B27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4049\/jimmunol.179.1.522","article-title":"The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation","volume":"179","year":"2007","journal-title":"J Immunol"},{"key":"key20180919073757_B28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/ng.590","article-title":"Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved","volume":"42","year":"2010","journal-title":"Nat Genet"},{"key":"key20180919073757_B29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/2049-632X.12144","article-title":"Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis","volume":"70","year":"2014","journal-title":"Pathog Dis"},{"key":"key20180919073757_B30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/2049-632X.12143","article-title":"Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules","volume":"70","year":"2014","journal-title":"Pathog Dis"},{"key":"key20180919073757_B31","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1128\/IAI.72.11.6622-6632.2004","article-title":"The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key20180919073757_B32","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","year":"2004","journal-title":"J Immunol"},{"key":"key20180919073757_B33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1073\/pnas.0712077106","article-title":"Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protection in cynomolgus monkeys","volume":"106","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073757_B34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults","volume":"188","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"key20180919073757_B35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","year":"2011","journal-title":"Nat Med"},{"key":"key20180919073757_B36","doi-asserted-by":"publisher","first-page":"e39909","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key20180919073757_B37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","year":"2012","journal-title":"J Clin Invest"},{"key":"key20180919073757_B38","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1128\/IAI.02145-14","article-title":"Protection against Mycobacterium leprae infection by the ID83\/GLA-SE and ID93\/GLA-SE vaccines developed for tuberculosis","volume":"82","year":"2014","journal-title":"Infect Immun"},{"key":"key20180919073757_B39","doi-asserted-by":"publisher","first-page":"e83884","DOI":"10.1371\/journal.pone.0083884","article-title":"A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"key20180919073757_B40","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/IAI.68.5.2888-2898.2000","article-title":"Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis","volume":"68","year":"2000","journal-title":"Infect Immun"},{"key":"key20180919073757_B41","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1128\/IAI.72.5.3031-3037.2004","article-title":"Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key20180919073757_B42","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1128\/IAI.73.2.1196-1203.2005","article-title":"Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis","volume":"73","year":"2005","journal-title":"Infect Immun"},{"key":"key20180919073757_B43","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1172\/JCI31947","article-title":"Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis","volume":"117","year":"2007","journal-title":"J Clin Invest"},{"key":"key20180919073757_B44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/eji.201141903","article-title":"Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory","volume":"42","year":"2012","journal-title":"Eur J Immunol"},{"key":"key20180919073757_B45","doi-asserted-by":"publisher","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key20180919073757_B46","doi-asserted-by":"publisher","first-page":"e45213","DOI":"10.1371\/journal.pone.0045213","article-title":"Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key20180919073757_B47","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.vaccine.2009.02.060","article-title":"Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073757_B48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.14573\/altex.1311041","article-title":"A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity","volume":"31","year":"2014","journal-title":"ALTEX"},{"key":"key20180919073757_B49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nm.2420","article-title":"A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis","volume":"17","year":"2011","journal-title":"Nat Med"},{"key":"key20180919073757_B50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.tube.2009.01.005","article-title":"Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs","volume":"89","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tube.2007.12.003","article-title":"Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model","volume":"88","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B52","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tube.2011.06.001","article-title":"Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis","volume":"91","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B53","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.smim.2014.09.009","article-title":"The formation of the granuloma in tuberculosis infection","volume":"26","year":"2014","journal-title":"Semin Immunol"},{"key":"key20180919073757_B54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018523","article-title":"Novel vaccination strategies against tuberculosis","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key20180919073757_B55","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/infdis\/jis941","article-title":"Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns","volume":"207","year":"2013","journal-title":"J Infect Dis"},{"key":"key20180919073757_B56","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1128\/CVI.00368-09","article-title":"Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis","volume":"17","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073757_B57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tube.2010.06.002","article-title":"The Achilles heel of BCG","volume":"90","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B58","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tube.2012.02.008","article-title":"A mouse model of tuberculosis reinfection","volume":"92","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B59","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1128\/IAI.01392-09","article-title":"Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon","volume":"78","year":"2010","journal-title":"Infect Immun"},{"key":"key20180919073757_B60","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1128\/IAI.00550-12","article-title":"Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset","volume":"80","year":"2012","journal-title":"Infect Immun"},{"key":"key20180919073757_B61","doi-asserted-by":"publisher","first-page":"e5930","DOI":"10.1371\/journal.pone.0005930","article-title":"Protection and polyfunctional T cells induced by Ag85B-TB10.4\/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key20180919073757_B62","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.tube.2014.05.001","article-title":"Memory T cell subsets in tuberculosis: what should we be targeting?","volume":"94","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B63","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.vaccine.2012.02.036","article-title":"Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073757_B64","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1128\/CVI.05127-11","article-title":"Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells","volume":"18","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073757_B65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1046\/j.1365-2249.2003.02171.x","article-title":"A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes","volume":"133","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"key20180919073757_B66","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1128\/IAI.69.4.2714-2717.2001","article-title":"Boosting vaccine for tuberculosis","volume":"69","year":"2001","journal-title":"Infect Immun"},{"key":"key20180919073757_B67","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1016\/j.vaccine.2005.12.066","article-title":"Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073757_B68","doi-asserted-by":"publisher","first-page":"e20404","DOI":"10.1371\/journal.pone.0020404","article-title":"Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"key20180919073757_B69","doi-asserted-by":"publisher","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"key20180919073757_B70","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tube.2013.08.010","article-title":"Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis","volume":"94","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tube.2005.07.002","article-title":"Safety issues regarding new vaccines for tuberculosis, with an emphasis on post-exposure vaccination","volume":"86","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B72","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/infdis\/jis425","article-title":"Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment","volume":"207","year":"2013","journal-title":"J Infect Dis"},{"key":"key20180919073757_B73","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4103\/0971-5916.90999","article-title":"Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis","volume":"134","year":"2011","journal-title":"Indian J Med Res"},{"key":"key20180919073757_B74","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.4049\/jimmunol.140.10.3589","article-title":"Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection","volume":"140","year":"1988","journal-title":"J Immunol"},{"key":"key20180919073757_B75","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(05)70240-1","article-title":"Exogenous reinfection in tuberculosis","volume":"5","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"key20180919073757_B76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s15010-008-8087-y","article-title":"A dynamic reinfection hypothesis of latent tuberculosis infection","volume":"37","year":"2009","journal-title":"Infection"},{"key":"key20180919073757_B77","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","article-title":"Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1-IL-2-secreting central memory cells","volume":"190","year":"2013","journal-title":"J Immunol"},{"key":"key20180919073757_B78","doi-asserted-by":"publisher","first-page":"19408","DOI":"10.1073\/pnas.1006298107","article-title":"Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection","volume":"107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073757_B79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1128\/AAC.00978-10","article-title":"Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key20180919073757_B80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tube.2009.08.004","article-title":"Evaluation of new vaccines for tuberculosis in the guinea pig model","volume":"89","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tube.2004.09.009","article-title":"Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis","volume":"85","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4049\/jimmunol.0903856","article-title":"Understanding latent tuberculosis: a moving target","volume":"185","year":"2010","journal-title":"J Immunol"},{"key":"key20180919073757_B83","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.tube.2009.09.002","article-title":"Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis","volume":"89","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"key20180919073757_B84","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/CVI.00079-10","article-title":"Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing","volume":"17","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073757_B85","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4049\/jimmunol.1400676","article-title":"Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge","volume":"193","year":"2014","journal-title":"J Immunol"},{"key":"key20180919073757_B86","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.3791\/3820","article-title":"Growth of Mycobacterium tuberculosis biofilms","volume":"pii","year":"2012","journal-title":"J Vis Exp"},{"key":"key20180919073757_B87","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2958.2008.06274.x","article-title":"Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria","volume":"69","year":"2008","journal-title":"Mol Microbiol"},{"key":"key20180919073757_B88","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1128\/IAI.72.4.2420-2424.2004","article-title":"Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung","volume":"72","year":"2004","journal-title":"Infect Immun"},{"key":"key20180919073757_B89","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.4049\/jimmunol.1401103","article-title":"Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis","volume":"193","year":"2014","journal-title":"J Immunol"},{"key":"key20180919073757_B90","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.tube.2011.12.003","article-title":"BCG: myths, realities, and the need for alternative vaccine strategies","volume":"92","year":"2012","journal-title":"Tuberculosis (Edinb)"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00718-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T04:12:01Z","timestamp":1690776721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00718-14"}},"subtitle":[],"editor":[{"given":"C. J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,24]]},"references-count":90,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,2,25]]},"published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/CVI.00718-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00718-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,24]]}}}